Ketamine G.L. Pharma (Ketamine)

Ketamine works by blocking the NMDA receptor, a key component of excitatory glutamate signaling in the central nervous system. This antagonism reduces neuronal firing, producing dissociative anesthesia, while downstream effects on other receptors and signaling pathways may contribute to rapid antidepressant activity.

The dose of Ketamine G.L. Pharma is determined by the prescribing clinician based on the intended use, patient characteristics, and procedural requirements. Dosage regimens are individualized and should follow established clinical guidelines and local regulatory standards.

Safety data for ketamine in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with agents such as propofol, ketamine provides analgesia and maintains cardiovascular stability, but it is more likely to cause dissociative experiences and hypertension. Choice of agent depends on the clinical scenario, patient comorbidities, and the need for analgesic versus purely hypnotic effects.

Ketamine G.L. Pharma should be stored at ambient temperature, protected from direct light and moisture, and kept in its original sealed container. Avoid freezing or exposing the solution to extreme temperatures to maintain product integrity.

The injectable solution is administered by a qualified healthcare professional via intravenous or intramuscular injection. The route, rate, and total dose are selected according to the clinical indication and patient response, with continuous monitoring during and after administration.

Serious risks include respiratory depression requiring airway support, severe hypertension that can lead to cardiovascular complications, and, with prolonged high‑dose use, urinary tract toxicity such as cystitis. Prompt recognition and appropriate monitoring are essential to mitigate these risks.

Ketamine should be avoided in individuals with known hypersensitivity to the drug, uncontrolled hypertension, severe cardiovascular disease, or certain psychiatric conditions that may be exacerbated by dissociative effects. It is also contraindicated in patients where alternative anesthetic options are safer.